Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase –Positive Non–Small Cell Lung Cancer
This study aimed to compare the relative efficacy of lorlatinib, an anaplastic lymphoma kinase –tyrosine kinase inhibitor, with chemotherapy, for patients with second-line or later advanced anaplastic lymphoma kinase–positive non–small cell lung cancer. The endpoints of interest were overall survival (OS) and progression-free survival (PFS).
Source: Value in Health - Category: International Medicine & Public Health Authors: Sarah Smith, Fernando Albuquerque de Almeida, Monica In ês, Laura Iadeluca, Miranda Cooper Tags: Comparative-Effectiveness Research/HTA Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | International Medicine & Public Health | Lung Cancer | Lymphoma | Study